RIBOCICLIB SUCCINATE
Get in touch with us!
Get in touch with us!
An Overview
INHIBITOR OF CYCLIN-DEPENDENT KINASE (CDK) 4 AND 6
Treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer as initial endocrine-based therapy.
Description / Use
- Product type: oncologic treatment
- CAS number: 1374639-75-4
- Common indications: breast cancer
- Product status: development
- Available grades: no micronized. Current PSD D90‹200µm; adaptable to customer needs
Properties
- Oral administration
- Applied to the most common subtype of breast cancer
- Potential global treatment candidates about 1.5 million people per year
- CAGR (2023-2033) over +7.3%
Advantages
- Polymorphic Form A (US9193732B2) confirmed.
- GMP Production capabilities up to 500 kg/year. Workshop OEB 4 with engineering control measures.
- Chinese manufacturer freedom to operate for this product.
- Development samples and standards available with CoA.
- Impurities deeply studied. Total impurities around 0.1%.
- Purity > 98%.
- No monograph in force. In compliance with general regulatory requirements. Stable room temperature.
- Industrial quantities available in Q3 2025.
- Competitive price based on market.
Final Product Innovator Presentations
- 200mg tablets.
- Combined targeted therapy with another hormonal drug (aromatase inhibitors and fulvestrant).
* Items covered by valid patents are not offered or supplied for commercial use. Products under patent are available for R&D use only.
Certifications






Our API
Ribociclib succinate
- Our API ribociclib succinate is manufactured in accordance with cGMP and stringent international quality standards.
Canagliflozin
- Our quality control follows every stage from development of analytical methods to the control of manufacturing process, enabling us to achieve rigorous and stringent results in accordance with injectables parameters, even under aseptic conditions.